The global brucellosis vaccine market size was estimated to be USD 251.1 million in 2023 and is expected to reach USD 421.0 million by 2034 with a CAGR of 4.81% during the forecast period 2024-2034. Increasing incidence of brucellosis, government initiatives and regulations, rising awareness about zoonotic diseases, advancements in vaccine technology, and increasing investments in healthcare and veterinary sectors will drive the market growth.
Particularly in developing nations, brucellosis continues to be a serious public health problem in many areas. The World Health Organization (WHO) projects that there are more than 500,000 new cases every year. The apparent expansion of the market is being aided by the detection of more instances as a result of enhanced diagnostics and more awareness. For instance, in October 2023, Zoetis Inc. purchased VetForm LLC, a business that specialized in biologics and animal feed additives. This acquisition may have allowed them to broaden their brucellosis management efforts beyond vaccinations.
By vaccine type, the subunit vaccines segment accounted for the highest revenue-grossing segment in the global brucellosis vaccine market in 2023 owing to the increasing preference for this vaccine type due to its targeted and specific antigenic components, which enhance safety and efficacy profiles. For instance, Merck & Co., Inc. strengthened their presence in high-burden regions in Africa by expanding their livestock vaccine distribution network in December 2023. Additionally, the DNA vaccines segment is predicted to grow at the fastest CAGR during the forecast period owing to the innovative approach of using genetic material to stimulate a robust immune response, thereby offering enhanced efficacy, prolonged immunity, and the potential for broader protection against various strains of Brucella.
By application, the cattle segment accounted for the highest revenue-grossing segment in the global brucellosis vaccine market in 2023 owing to the substantial economic losses associated with brucellosis outbreaks in cattle, compelling livestock owners to invest in preventive measures. For instance, in November 2023, Bayer AG said that it was collaborating with a Chinese university to create a novel recombinant vaccination for sheep and goats, with the aim of catering to the expanding small ruminant market. Additionally, the sheep & goat segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding small ruminant farming industry, increasing recognition of brucellosis as a significant threat to these livestock populations, and a rising emphasis on preventive healthcare measures.
By end-user, the veterinary hospitals & clinics segment accounted for the highest revenue-grossing segment in the global brucellosis vaccine market in 2023 owing to the increasing trend of pet owners and livestock farmers seeking professional veterinary services for disease prevention and management. For instance, Boehringer Ingelheim International GmbH in July 2023. teamed up with a nonprofit in Africa to offer education and materials for the prevention of brucellosis, including immunization campaigns. Additionally, the government vaccination programs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of brucellosis as a public health concern and the imperative role of governments in implementing widespread preventive measures.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust regulatory framework, increased awareness about brucellosis prevention, and substantial investments in veterinary healthcare. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the expanding livestock industry, rising awareness about zoonotic diseases, and increasing governmental focus on agricultural and animal health. For instance, Indian Immunologicals Limited in December 2023. shown their manufacturing prowess by producing and delivering a sizable quantity of livestock vaccinations to a Southeast Asian government program.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Particularly in developing nations, brucellosis continues to be a serious public health problem in many areas. The World Health Organization (WHO) projects that there are more than 500,000 new cases every year. The apparent expansion of the market is being aided by the detection of more instances as a result of enhanced diagnostics and more awareness. For instance, in October 2023, Zoetis Inc. purchased VetForm LLC, a business that specialized in biologics and animal feed additives. This acquisition may have allowed them to broaden their brucellosis management efforts beyond vaccinations.
By vaccine type, the subunit vaccines segment accounted for the highest revenue-grossing segment in the global brucellosis vaccine market in 2023 owing to the increasing preference for this vaccine type due to its targeted and specific antigenic components, which enhance safety and efficacy profiles. For instance, Merck & Co., Inc. strengthened their presence in high-burden regions in Africa by expanding their livestock vaccine distribution network in December 2023. Additionally, the DNA vaccines segment is predicted to grow at the fastest CAGR during the forecast period owing to the innovative approach of using genetic material to stimulate a robust immune response, thereby offering enhanced efficacy, prolonged immunity, and the potential for broader protection against various strains of Brucella.
By application, the cattle segment accounted for the highest revenue-grossing segment in the global brucellosis vaccine market in 2023 owing to the substantial economic losses associated with brucellosis outbreaks in cattle, compelling livestock owners to invest in preventive measures. For instance, in November 2023, Bayer AG said that it was collaborating with a Chinese university to create a novel recombinant vaccination for sheep and goats, with the aim of catering to the expanding small ruminant market. Additionally, the sheep & goat segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding small ruminant farming industry, increasing recognition of brucellosis as a significant threat to these livestock populations, and a rising emphasis on preventive healthcare measures.
By end-user, the veterinary hospitals & clinics segment accounted for the highest revenue-grossing segment in the global brucellosis vaccine market in 2023 owing to the increasing trend of pet owners and livestock farmers seeking professional veterinary services for disease prevention and management. For instance, Boehringer Ingelheim International GmbH in July 2023. teamed up with a nonprofit in Africa to offer education and materials for the prevention of brucellosis, including immunization campaigns. Additionally, the government vaccination programs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of brucellosis as a public health concern and the imperative role of governments in implementing widespread preventive measures.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust regulatory framework, increased awareness about brucellosis prevention, and substantial investments in veterinary healthcare. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the expanding livestock industry, rising awareness about zoonotic diseases, and increasing governmental focus on agricultural and animal health. For instance, Indian Immunologicals Limited in December 2023. shown their manufacturing prowess by producing and delivering a sizable quantity of livestock vaccinations to a Southeast Asian government program.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Vaccine Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Brucellosis Vaccine Market Report 2023 - 2034
Brucellosis Vaccine Market Analysis & Forecast by Vaccine Type 2023 - 2034 (Revenue USD Mn)
- DNA Vaccine
- Subunit Vaccine
- Vector Vaccine
- Recombinant Vaccine
Brucellosis Vaccine Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Cattle
- Sheep & Goat
- Others
Brucellosis Vaccine Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Mn)
- Veterinary Hospitals & Clinics
- Animal Care Centers
- Others
Brucellosis Vaccine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Brucellosis Vaccine Market: Vaccine Vaccine Type Estimates & Trend Analysis
8. Brucellosis Vaccine Market: Application Estimates & Trend Analysis
9. Brucellosis Vaccine Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Brucellosis Vaccine Market
12. Europe Global Brucellosis Vaccine Market
13. Asia Pacific Global Brucellosis Vaccine Market
14. Latin America Global Brucellosis Vaccine Market
15. MEA Global Brucellosis Vaccine Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Zoetis Inc.
- Merck & Co. Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Indian Immunologicals Limited
- HIPRA
- Syntellys Biotech
- Colorado Serum Company
- Hester Biosciences Limited
- CZ Veterinaria
- Valneva SE
- TECON Group
- Meibao Biotechnology Co. Ltd.
- Biogenesis Bago S.A.
- Razi Vaccine and Serum Research Institute.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 251.1 Million |
| Forecasted Market Value ( USD | $ 421 Million |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
